Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kyung-Soo Kim (Kim KS), Byung-Wan Lee (Lee BW), Yong Jin Kim (Kim YJ), Dae Ho Lee (Lee DH), Bong-Soo Cha (Cha BS), Cheol-Young Park (Park CY)
Diabetes Metab J. 2019;43(2):127-143.   Published online 2019 Apr 15     DOI:
Citations to this article as recorded by Crossref logo
Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
Obesity.2022; 30(6): 1279.     CrossRef
Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
Journal of General Internal Medicine.2022; 37(16): 4153.     CrossRef
Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
Kyung-Soo Kim
The Journal of Korean Diabetes.2022; 23(2): 83.     CrossRef
Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
Frontiers in Pharmacology.2022;[Epub]     CrossRef
Intestinal microbiota in the treatment of metabolically associated fatty liver disease
Ji-Shuai Wang, Jin-Chun Liu
World Journal of Clinical Cases.2022; 10(31): 11240.     CrossRef
Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko
Systemic Hypertension.2022; 19(1): 31.     CrossRef
Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
Nutrients.2022; 14(23): 4994.     CrossRef
Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch
Preventive Nutrition and Food Science.2022; 27(4): 384.     CrossRef
NAFLD in type 2 diabetes mellitus: Still many challenging questions
Simona Cernea, Itamar Raz
Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171.     CrossRef
Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Sook Jung Lee, Byung-Wan Lee
The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
NAFLD and its link with diabetes: Why we should be worried
Louise Cremonesini, Emma Harkin
Independent Nurse.2021; 2021(8): 20.     CrossRef
Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi
Archives of Physiology and Biochemistry.2020; : 1.     CrossRef
Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
Cardiovascular Diabetology.2020;[Epub]     CrossRef
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
The Lancet Gastroenterology & Hepatology.2020; 5(9): 829.     CrossRef
Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
Medicine.2020; 99(33): e21038.     CrossRef
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
Metabolism.2020; 111: 154299.     CrossRef
Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
Siôn A. Parry, Leanne Hodson
Advances in Therapy.2020; 37(4): 1381.     CrossRef
Diabetes and Metabolism Journal in 2020: Good to Great
In-Kyung Jeong
Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
Pharmacological Research.2020; 159: 104984.     CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao
Journal of Diabetes Investigation.2020; 11(5): 1238.     CrossRef
Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef